Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  etanidazole
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
Phase II/III Comparison of Radiotherapy with vs without the Hypoxic Cell Sensitizer SR-2508 in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-8527, RTOG-85-27
Phase II Study of the Radiosensitizer SR 2508 with Radiotherapy in Patients with Locally Extensive Prostate Adenocarcinoma (Summary Last Modified 05/91)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-87022, NCI-T87-0077O, T87-0077
Phase II Study of External Beam Radiotherapy with Etanidazole in Patients with Locally Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9020, RTOG-90-20
Phase IB Study of Radiosurgery plus SR-2508 for Recurrent Primary Brain Tumors or CNS Metastases
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9502, RTOG-95-02
Phase I Trial of the Hypoxic Cell Radiosensitizer SR-2508
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-8303, NCI-83-C-56
Phase I Radiosensitization with Continuous Infusion SR-2508 in Patients Undergoing Interstitial or Intracavitary Radiotherapy for Control of Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-8605, DFCI-86020, RTOG-86-05
Phase I Chemosensitization with SR-2508 plus Chemotherapy with CTX in Patients with Solid Tumors (Summary Last Modified 04/88)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: FCCC-86820, NCI-T86-0235D, T86-0235
Phase I Assessment of Clinical, Biological, and Pharmacologic Effects of Intravenous SR-2508 and CTX in Patients with Advanced Malignancies (Summary Last Modified 09/89)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-8793, NCI-T87-0070C, T87-0070
Phase I Evaluation of CTX plus SR-2508 in Patients with Relapsing or Refractory Adult Chronic Lymphocytic Leukemia (Summary Last Modified 12/89)
Phase: Phase I
Type: Treatment
Status: Closed
Age: adult
Sponsor: NCI
Protocol IDs: WSU-C-72587, NCI-T88-0026D, T88-0026
Phase I Study of Chemotherapy with Intravenous L-PAM/PRED and the Sensitizer SR-2508 (Etanidazole) in Patients with Multiple Myeloma (Summary Last Modified 11/89)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: DFCI-88157, NCI-T89-0014D, T89-0014
Phase I Study of Radiotherapy, Etanidazole, CDDP, and Hyperthermia in Patients with Superficial Tumors (Summary Last Modified 04/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-89128, NCI-T89-0211D, T89-0211
Phase I Study of Etanidazole and Radiotherapy in Patients with Malignant Glioma (Summary Last Modified 08/91)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: DFCI-90030, NCI-T90-0050O, T90-0050
Phase I Study of CBDCA/CTX/SR-2508 in Patients with Advanced Ovarian Cancer (Summary Last Modified 10/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: DFCI-90045, NCI-T90-0056O, T90-0056
Phase I Trial of Radiotherapy with SR-2508 Radiosensitization for Pediatric Brainstem Gliomas (Summary Last Modified 04/98)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 2 to 25
Sponsor: NCI
Protocol IDs: DFCI-90080, NCI-T90-0158O, T90-0158
Phase I Study of ICE (IFF/CBDCA/VP-16) with Hematopoietic Stem Cell Support and Dose Escalation of SR-2508 in Patients with Advanced Malignancies (Summary Last Modified 12/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to physiologic 55
Sponsor: NCI
Protocol IDs: DFCI-91110, NCI-T91-0221D, T91-0221
Phase I Study of SR-2508 with ICE (IFF/CBDCA/VP-16) in Patients with Advanced non-Small Cell Lung Cancer and Other Advanced Malignancies (Summary Last Modified 09/92)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18
Sponsor: NCI
Protocol IDs: DFCI-91111, NCI-T91-0220D, T91-0220
Phase I Study of CBDCA/CTX with SR-2508 and G-CSF in Patients with Advanced Ovarian Cancer (Summary Last Modified 03/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: BWH-92-5604-01, DFCI-92090, NCI-T92-0141O, T92-0141
Start Over